Status:

COMPLETED

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)

Lead Sponsor:

Novo Nordisk A/S

Conditions:

Diabetes Mellitus, Type 2

Eligibility:

All Genders

18+ years

Brief Summary

The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 ...

Eligibility Criteria

Inclusion

  • Signed informed consent obtained before any study-related activities (study-related activities are any procedures related to recording of data according to protocol)
  • The decision to initiate treatment with commercially available semaglutide has been made by the patient/Legally Acceptable Representative and the treating physician before and independently from the decision to include the patient in this study
  • Male or female, age greater than or equal to 18 years at the time of signing informed consent
  • Diagnosed with type 2 diabetes at least 12 weeks prior to inclusion
  • Available and documented haemoglobin A1c (HbA1c) value less than or equal to 12 weeks prior to initiation of semaglutide treatment

Exclusion

  • Previous participation in this study. Participation is defined as having given informed consent in this study
  • Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
  • Treatment with any investigational drug within 90 days prior to enrolment into the study
  • Hypersensitivity to semaglutide or to any of the excipients

Key Trial Info

Start Date :

September 16 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

September 27 2021

Estimated Enrollment :

521 Patients enrolled

Trial Details

Trial ID

NCT04083820

Start Date

September 16 2019

End Date

September 27 2021

Last Update

March 28 2023

Active Locations (53)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 14 (53 locations)

1

Novo Nordisk Investigational Site

Angers, France, 37540

2

Novo Nordisk Investigational Site

Annecy, France, 74600

3

Novo Nordisk Investigational Site

Auffay, France, 76720

4

Novo Nordisk Investigational Site

Avignon, France, 84902

A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE) | DecenTrialz